New research shows that an existing type 2 diabetes drug also significantly decreases the risk of other serious conditions. A study published in the
Renal-related events specifically were to be measured as part of a post-approval safety exploration of canagliflozin (brand name Invokana and Invokamet, Janssen Pharmaceuticals, a Johnson and Johnson company). The published research combined the new